Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bordetella pertussis CHIM Dose-Escalation Study
NCT05136599Phase 1Completed
- Sponsor
- Dalhousie University
- Start
- Jan 2022
- Primary completion
- Mar 2025
- Modality
- Bacterial Strains
- Countries
- 1
01
Overview
Phase 1, open-label trial of bordetella pertussis d420 in pertussis (8 arms), sponsored by Dalhousie University. Primary endpoint: Number of Participants With Pertussis Infection With Mild Symptoms of Early Pertussis Disease Postchallenge. Started Jan 2022; status: completed.
02
Drugs
bordetella pertussis d420
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT05136599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136599.